Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92

Market Focus08-27

On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.

Within the Biotechnology sector where Madrigal Pharmaceuticals belongs, the stock notably outperformed peers. Among individual stocks, Moderna down 7.67%, Revolution Medicines down 0.07%, Amgen down 0.16%, AbbVie down 1.61%, Gilead Sciences down 0.03%.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its core product Rezdiffra is a once-daily oral liver-directed thyroid hormone receptor beta agonist. The company reported Q2 Rezdiffra net sales of $364.3 million, representing 71% year-over-year growth, with more than 49,000 patients on therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1157140095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 03:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1157140095","market":"us","top_or_hot":-1,"title":"Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92","media":"Market Focus","content":"<p><p>On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.</p><p>Within the Biotechnology sector where Madrigal Pharmaceuticals belongs, the stock notably outperformed peers. Among individual stocks, Moderna down 7.67%, Revolution Medicines down 0.07%, Amgen down 0.16%, AbbVie down 1.61%, Gilead Sciences down 0.03%.</p><p>Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its core product Rezdiffra is a once-daily oral liver-directed thyroid hormone receptor beta agonist. The company reported Q2 Rezdiffra net sales of $364.3 million, representing 71% year-over-year growth, with more than 49,000 patients on therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Madrigal Pharmaceuticals Rises 5.08% in Regular Trading, Trading at $537.92\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 03:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.</p><p>Within the Biotechnology sector where Madrigal Pharmaceuticals belongs, the stock notably outperformed peers. Among individual stocks, Moderna down 7.67%, Revolution Medicines down 0.07%, Amgen down 0.16%, AbbVie down 1.61%, Gilead Sciences down 0.03%.</p><p>Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its core product Rezdiffra is a once-daily oral liver-directed thyroid hormone receptor beta agonist. The company reported Q2 Rezdiffra net sales of $364.3 million, representing 71% year-over-year growth, with more than 49,000 patients on therapy.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1157140095","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1157140095","pubTimestamp":1787770920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.Within the Biotechnology sector where Madrigal Pharmaceuticals belongs,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"走势提醒|牧歌制药常规交易上涨 5.08%，交易价格为 537.92 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"On August 27, Madrigal Pharmaceuticals rose 5.08% in regular trading, trading at $537.92/share, with Turnover of $124 million.Within the Biotechnology sector where Madrigal Pharmaceuticals belongs, the stock notably outperformed peers. Among individual stocks, Moderna down 7.67%, Revolution Medicines down 0.07%, Amgen down 0.16%, AbbVie down 1.61%, Gilead Sciences down 0.03%.Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its core product Rezdiffra is a once-daily oral liver-directed thyroid hormone receptor beta agonist. The company reported Q2 Rezdiffra net sales of $364.3 million, representing 71% year-over-year growth, with more than 49,000 patients on therapy.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1157140095","isCrawlerRequest":true}